R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. That was one of the key messages from SynBioBeta’s Synthetic Biology Biopharma Conference last month ...

R&amp,D outsourcing involves pharmaceutical companies subcontracting parts of their R&amp,D efforts to third-party service providers. Small or mid-sized pharmaceutical or biotech houses may use ...

Explore how India's 20-year product patent regime transformed its pharma industry from generics to innovation, the economic ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020 ...

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with ...

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...

While the government is striving hard to boost exports to achieve sustainable economic growth, the pharmaceutical ...

CHENNAI: Shares of India's largest drug maker Sun Pharmaceutical Industries fell almost 1% on main stock exchanges on ...

Pakistan's pharmaceutical manufacturers are urging the government to redirect a mandatory 1% profit contribution, currently channelled into a centralised ...